Page 258 - Drug Class Review
P. 258

Page 159 of 205
             Drug Effectiveness Review Project






























                                 placebo   75.7%   9.0%   7.6%   5.6%                         placebo   32.6%   6.3%























                                 donepezil   81.7%   11.3%   11.3%   10.6%   Post randomization exclusions: NR   Overall loss to follow-up: 32.9%  Loss to follow-up differential high: No   donepezil   33.1%   7%







                                                            ITT: Yes


                                                  NR               Yes      NR   NR                             Fair
















             Final Report Update 1    Authors: Winblad et al. 2001   Year: 2001   ADVERSE EVENTS:   Overall adverse effects reported:   Nausea   •   Depression   •   Anxiety   •  Significant differences in adverse   events:      ANALYSIS:    ADEQUATE RANDOMIZATION:   ADEQUATE ALLOCATION   CONCEALMENT:  BLINDING OF OUTCOME   ASSESSORS:   ATTRITION (overall):     ATTRITION (treatment specific):   Loss to follow-up:   Withdrawals due to adverse events:        QUALITY RATING:      *primary outcome measures        Alzheimer's Drugs
   253   254   255   256   257   258   259   260   261   262   263